アブストラクト
| Title | 内分泌障害 |
|---|---|
| Subtitle | 特集 有害事象の専門診療科からみた免疫チェックポイント阻害薬の副作用対策 |
| Authors | 岩間信太郎* |
| Authors (kana) | |
| Organization | *名古屋大学医学部附属病院・糖尿病・内分泌内科 |
| Journal | 癌と化学療法 |
| Volume | 47 |
| Number | 2 |
| Page | 203-206 |
| Year/Month | 2020 / 2 |
| Article | 報告 |
| Publisher | 癌と化学療法社 |
| Abstract | 「要旨」 免疫チェックポイント阻害薬(ICIs)は進行悪性腫瘍に広く使用されるようになった. 本薬剤による治療では肺, 皮膚, 消化管, 肝, 神経・筋, 内分泌器官など全身の様々な臓器において免疫関連有害事象(immune-related adverse events: irAEs)と呼ばれる副作用が生じる. 内分泌irAEsとして下垂体機能低下症, 副腎皮質機能低下症, 甲状腺機能異常症, 副甲状腺機能低下症, 1型糖尿病が報告されている. 内分泌irAEsを発症すると副腎クリーゼ, 甲状腺クリーゼ, 低カルシウム血症, 糖尿病ケトアシドーシスから重篤な転帰となる可能性があるため, それぞれの特徴を理解して適切にマネジメントすることが極めて重要である. 最近われわれは, 抗PD-1抗体のニボルマブ治療において, 治療開始前の甲状腺自己抗体が甲状腺機能異常症の高リスクマーカーとなることを明らかにした. |
| Practice | 臨床医学：一般 |
| Keywords | Hypopituitarism, Hypoadrenalism, Thyroid dysfunction, Hypoparathyroidism, Type 1 diabetes |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) 日本内分泌学会: -日本内分泌学会臨床重要課題-免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日内分泌会誌 94(Suppl): 1-11, 2018.
- 2) Arima H, Iwama S, Inaba H, et al: Management of im-mune-related adverse events in endocrine organs in-duced by immune checkpoint inhibitors: clinical guide-lines of the Japan Endocrine Society. Endocr J 66(7): 581-586, 2019.
- 3) Caturegli P, Di Dalmazi G, Lombardi M, et al: Hypophysi-tis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186(12): 3225-3235, 2016.
- 4) Iwama S, De Remigis A, Callahan MK, et al: Pituitary ex-pression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6(230): 230ra45, 2014.
- 5) Faje AT, Lawrence D, Flaherty K, et al: High-dose glu-cocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in pa-tients with melanoma. Cancer 124(18): 3706-3714, 2018.
残りの15件を表示する
- 6) Min L, Hodi FS, Giobbie-Hurder A, et al: Systemic high-dose corticosteroid treatment does not improve the out-come of ipilimumab-related hypophysitis: a retrospec-tive cohort study. Clin Cancer Res 21(4): 749-755, 2015.
- 7) Yanase T, Tajima T, Katabami T, et al: Diagnosis and treatment of adrenal insufficiency including adrenal cri-sis: a Japan Endocrine Society clinical practice guideline. Endocr J 63(9): 765-784, 2016.
- 8) Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a sys-tematic review and meta-analysis. JAMA Oncol 4(2): 173-182, 2018.
- 9) Neppl C, Kaderli RM, Trepp R, et al: Histology of nivolu-mab-induced thyroiditis. Thyroid 28(12): 1727-1728, 2018.
- 10) Angell TE, Min L, Wieczorek TJ, et al: Unique cytologic features of thyroiditis caused by immune checkpoint in-hibitor therapy for malignant melanoma. Genes Dis 5(1): 46-48, 2018.
- 11) McMillen B, Dhillon MS and Yong-Yow S: A rare case of thyroid storm. BMJ Case Rep: 2016. doi:10.1136/bcr-2016-214603.
- 12) Ma C, Hodi FS, Giobbie-Hurder A, et al: The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders. Cancer Immunol Res 7(7): 1214-1220, 2019.
- 13) Kobayashi T, Iwama S, Yasuda Y, et al: Patients with an-tithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2(3): 241-251, 2018.
- 14) Kimbara S, Fujiwara Y, Iwama S, et al: Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109(11): 3583-3590, 2018.
- 15) Piranavan P, Li Y, Brown E, et al: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab 104(2): 550-556, 2019.
- 16) Baden MY, Imagawa A, Abiru N, et al: Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10(1): 58-66, 2019.
- 17) Clotman K, Janssens K, Specenier P, et al: Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 103(9): 3144-3154, 2018.
- 18) 日本糖尿病学会: 免疫チェックポイント阻害薬使用患者における1型糖尿病の発症に関するRecommendation, 2016. http://www.fa.kyorin.co.jp/jds/uploads/recommendation_nivolumab.pdf
- 19) Osorio JC, Ni A, Chaft JE, et al: Antibody-mediated thy-roid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3): 583-589, 2017.
- 20) Yamauchi I, Yasoda A, Matsumoto S, et al: Incidence, fea-tures, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 14(5): e0216954, 2019.
